Search

Search Constraints

You searched for: Author/Creator Leist, Thomas

Search Results

1. 022  Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data. Issue 6 (27th May 2022)

2. 040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. Issue 6 (24th May 2018)

5. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. (January 2022)

6. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Issue 5 (September 2018)

7. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022)

9. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. (May 2023)